--- canonical_name: Testagen alternate_names: KEDG, Lys-Glu-Asp-Gly, H-Lys-Glu-Asp-Gly-OH, AKS-S canonical_topic: Testagen for Health & Longevity short_topic_lc: testagen creation_date: 2026-0930-0013 creator_ai_fullname: Opus 5.5 ep_keywords: Peptide Bioregulators, Khavinson Peptides, Cytogens, Short Peptides, Tetrapeptides --- # Testagen for Health & Longevity
Evidence Review created on 09/30/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** KEDG, Lys-Glu-Asp-Gly, H-Lys-Glu-Asp-Gly-OH, AKS-S ## Motivation Testagen is a lab-made chain of four amino acids sold as a "bioregulator" for the male reproductive system. It belongs to a family of short peptides created by a Russian research group that holds that tiny, organ-specific peptides can switch cells in their matching organ back toward healthier activity. Its sequence was modeled on peptide extracts from animal testes, and it draws interest from men who want to protect hormone output and fertility as they age. Testagen reaches most buyers through online peptide vendors and a Russian supplement line built by the same group that designed it. The research behind it is small, comes mostly from that group and its partners, and was carried out mainly in birds, cell cultures, and test tubes, with a single small study in men. It sits within a wider movement toward organ-targeted peptides for healthy aging. This review examines what is known about Testagen's biology, the claimed benefits for male hormones, fertility, and aging, the potential risks, how it is used, and how the quality and independence of the evidence shape what can be concluded. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists primary research and a podcast episode on Testagen (KEDG) and the peptide family it belongs to. - [Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA](https://pubmed.ncbi.nlm.nih.gov/22117547/) - Fedoreyeva et al., 2011 The one cell study naming "testagen": it enters human cell nuclei and binds specific DNA sequences. The peptide's developer is a co-author, and his institute sells Testagen. - [Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens](https://pubmed.ncbi.nlm.nih.gov/22268052/) - Kuznik et al., 2011 The main whole-animal study of KEDG: 40 days of injections in pituitary-removed birds, measuring thyroid hormones and gland structure, with a young-versus-old comparison. - [Efficacy of Testosterone Synthesis Inductor Application "Testagen" in Androgenic Deficiency in Patients with Chronic Abacterial Prostatitis](https://jpep.endocrinology.org.ua/index.php/1/article/view/747) - Rossikhin et al., 2011 The only published human study of Testagen: 36 men with chronic prostatitis (prostate inflammation) and low testosterone; 20 received it with standard therapy for one month, 16 standard therapy alone; no placebo, randomization unreported. - [Peptides: The Science, Uses & Safety – Dr. Abud Bakri](https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri) - Andrew Huberman Podcast discussion of Khavinson's organ-specific peptide bioregulators (epithalon, pinealon, thymalin), the gene-regulation theory and short on-off courses that Testagen shares; Testagen itself is not named. Only four items qualified: the literature on Testagen is very small, and the one-item-per-source rule excluded further papers from the same two research groups, including a developer-authored review. No directly relevant content on Testagen or on Khavinson peptide bioregulators was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine, or Lifespan.io; searches of each platform returned no such discussion. ## Grokipedia [Testagen (peptide)](https://grokipedia.com/page/Testagen_peptide) A compact overview of sequence, chemistry, proposed DNA and protein binding, and the bird thyroid studies; it states no human data exist, overlooking a small 2011 clinical report, and relies partly on vendor sources. ## Examine No Examine article on Testagen exists. Examine.com does not typically cover research peptides that are not sold as mainstream supplements. ## ConsumerLab No ConsumerLab article on Testagen exists. ConsumerLab does not typically test research peptides or Russian peptide supplements. ## Systematic Reviews No systematic reviews or meta-analyses for Testagen were found on PubMed as of 09/30/2026. No systematic review or meta-analysis addresses Testagen's claimed benefits or its risks; both remain unrepresented. ## Mechanism of Action Testagen is a tetrapeptide (a chain of four amino acids: lysine, glutamic acid, aspartic acid, glycine; molecular weight about 447 daltons). The Khavinson group describes it as modeled on testicular peptide extracts, while a group at Chita State Medical Academy describes the same sequence as derived from anterior pituitary (front lobe of the brain's master hormone gland) extracts. - **Proposed nuclear action:** fluorescence-labeled Testagen enters the nucleus of HeLa cells (a human cancer cell line) and binds DNA fragments, preferring those containing the three-letter motif CAG ([Fedoreyeva et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22117547/)). It also binds histones (the spool proteins DNA wraps around), proposed to open genes for reading β€” an epigenetic effect (a change in gene activity without a change in DNA sequence) ([Fedoreyeva et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23581987/)). This work is co-authored by the developer, whose institute sells Testagen. - **Proposed cell entry:** computer docking predicts uptake through LAT1/LAT2 (amino-acid transporters) and PEPT1 (a gut peptide transporter) ([Khavinson et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36979488/)). - **Competing view:** measured binding is weak, and short peptides are normally cut into amino acids by peptidases (protein-cutting enzymes) in gut and blood, so delivery of intact Testagen to testicular cells is unproven. - **Pharmacology:** no pharmacokinetic study (measurement of absorption and clearance) exists; half-life, selectivity, and tissue distribution are unmeasured. Similar tetrapeptides are cleared within minutes by peptidase breakdown; no CYP (liver drug-metabolizing enzyme) pathway is expected. ## Historical Context & Evolution Testagen grew out of a Soviet military-medicine program begun in the 1970s by Vladimir Khavinson and Vyacheslav Morozov, who extracted peptide mixtures from calf organs (the thymus, an immune-training gland; the pineal gland, a small brain gland that makes melatonin; and later the testes) and proposed that each organ's peptides restore function in the same organ. Their thymus and pineal extracts became registered Russian medicines. In the 1990s and 2000s the group, based from 1992 at the St. Petersburg Institute of Bioregulation and Gerontology, which develops and sells these peptides, identified short sequences in the extracts and synthesized them as defined di-, tri-, and tetrapeptides. - **Original intended use:** Testagen was marketed in Russia as a dietary supplement for male reproductive function, sold alongside Testoluten, a natural testicular extract from the same developers. - **Research record:** KEDG first appears in indexed literature in 2008 ([Kuznik et al., 2008](https://pubmed.ncbi.nlm.nih.gov/19024016/)), in Chita studies of thyroid and thymus in pituitary-removed chickens. From 2011 the developer's partners reported DNA and histone binding, and a Kharkiv–Belgorod urology group reported the only human trial ([Rossikhin et al., 2011](https://jpep.endocrinology.org.ua/index.php/1/article/view/747)). - **Path to health optimization:** interest outside Russia arose in the 2020s through online peptide vendors and self-experimenting men seeking testosterone support without hormone replacement. What changed over time is the scale of claims, not the evidence: beyond that small trial without a placebo, no study has measured testosterone, sperm, or testicular tissue after Testagen, and independent groups have neither confirmed nor refuted the reproductive claims. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: the only human data come from one small trial without a placebo group or reported randomization, and the remaining data are bird experiments and cell-free binding assays. ### Medium 🟩 🟩 #### Higher Testosterone in Men with Chronic Prostatitis In 36 men aged 38–49 with chronic non-bacterial prostatitis and low testosterone, 20 given one month of Testagen plus standard therapy showed higher total testosterone, while 16 given standard therapy alone did not ([Rossikhin et al., 2011](https://jpep.endocrinology.org.ua/index.php/1/article/view/747)). Allocation and blinding were not reported, there was no placebo, and each group was compared only with baseline. Most men were overweight with sleep apnea (breathing pauses in sleep), which is linked to lower testosterone ([Su et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34536053/)). Men without prostatitis are unstudied. **Magnitude:** Total testosterone rose from a baseline of 7.1 nmol/L (about 205 ng/dL) to 9.8 nmol/L (about 283 ng/dL) after one month with Testagen, versus 7.5 nmol/L (about 216 ng/dL) with standard therapy alone; significance was reported only against baseline. #### Less Prostate Inflammation and Better Urine Flow In the same trial, symptom scores on the NIH-CPSI (a validated chronic prostatitis symptom questionnaire from the US National Institutes of Health) ([Litwin et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10411041/)), prostate-fluid white cells, and urine flow improved more with Testagen plus standard therapy than with standard therapy alone ([Rossikhin et al., 2011](https://jpep.endocrinology.org.ua/index.php/1/article/view/747)). Standard therapy alone also improved them. Without reported randomization, a placebo, or between-group testing, the share due to Testagen is uncertain. **Magnitude:** After one month, the NIH-CPSI score fell from 16.1 to 9.8 with Testagen versus 11.5 with standard therapy alone; mean urine flow rose from 13.5 to 17.4 mL/s versus 15.1 mL/s; prostate-fluid white cells fell from 28.2 to 15.4 per field versus 25.6. ### Low 🟩 ### Speculative 🟨 #### Sperm Production and Libido Vendors claim Testagen revives Leydig cells (testosterone-producing testicular cells), sperm production, and libido. No study, human or animal, has measured sperm or libido after Testagen. The basis is mechanistic and anecdotal only. #### Thyroid Hormone Recovery After Pituitary Loss In pituitary-removed chickens, 40 days of KEDG raised TSH (thyroid-stimulating hormone) and the thyroid hormones T3 and T4, preserving gland structure ([Kuznik et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22268052/)). Old hens responded less. Animal data only. #### Thymus and Immune Recovery In the same bird model, KEDG restored thymus structure ([Pateyk et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23658898/)) and normalized immune and clotting indices ([Kuznik et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20731122/)). No mammalian or human data exist. #### Slower Aging and Longer Lifespan Sister thymus and pineal peptides extended rodent lifespan in developer-run studies ([a review by Anisimov & Khavinson, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)). Testagen itself has never been tested for lifespan or aging markers. Basis is extrapolation only. ## Benefit-Modifying Factors - **Genetic polymorphisms:** no gene variant has been studied for Testagen response. Men with genetic testicular failure, such as Klinefelter syndrome (an extra X chromosome that scars the testes), have little functional tissue for a tissue-restoring peptide to act upon. - **Baseline biomarkers:** the only human data involve men with low testosterone, and the positive animal data involve pituitary-hormone deficiency. Whether low testosterone with high LH (luteinizing hormone, the pituitary signal driving testosterone) or with low LH responds differently is untested. - **Sex:** Testagen is designed and marketed for men. The bird studies included hens, but no female reproductive rationale or data exist. - **Pre-existing conditions:** the only human data come from men with chronic prostatitis. Conditions that already suppress testicular output, such as obesity, sleep apnea (breathing pauses in sleep), opioid use, or prior anabolic-steroid use, would confound any perceived benefit; none has been studied with Testagen. - **Age:** old hens showed weaker thyroid recovery than young chickens, suggesting smaller effects later in life. No age-specific data exist in men, including those over 65. ## Potential Risks & Side Effects ### High πŸŸ₯ πŸŸ₯ πŸŸ₯ No risk reaches High: the one small human study of Testagen reports no adverse-event data, and no prescribing information exists. ### Medium πŸŸ₯ πŸŸ₯ No risk reaches Medium: there is no single trial or consistent observational dataset on Testagen adverse events in people. ### Low πŸŸ₯ #### Substandard or Contaminated Product Testagen is mostly sold as unregulated "research use only" vials. Tests of a comparable online-bought injectable peptide found low purity and endotoxin (fever-causing bacterial toxin) in every vial ([Ashraf et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39509151/)); a case report describes illness after counterfeit semaglutide use ([Sterckx & De Keyser, 2026](https://pubmed.ncbi.nlm.nih.gov/41773123/)). No Testagen testing exists. **Magnitude:** In tested online semaglutide vials, purity was 7.7–14.4% against 99% claimed and endotoxin was present in 3 of 3 samples; no equivalent figure exists for Testagen. ### Speculative 🟨 #### Thyroid Hormone Shifts The bird studies show KEDG moves TSH, T3, and T4 ([Kuznik et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22268052/)). Whether it shifts thyroid levels in people with an intact pituitary is unknown. Animal data only. #### Immune-System Changes In pituitary-removed birds, KEDG normalized immune indices ([Kuznik et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20731122/)). In autoimmune disease or after transplantation, any immune stimulation could provoke flares or rejection. Animal data only; no human reports. #### Clotting Changes In the same bird model, KEDG normalized clotting and clot-dissolving indices ([Kuznik et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20731122/)). Whether it alters clotting in people, alone or with blood thinners, is unknown. Animal data only; no human reports. #### Stimulation of Hormone-Sensitive or Abnormal Tissue If Testagen activated growth genes or raised testosterone, prostate or undetected tumor growth could be stimulated. The developers instead propose anti-tumor effects. Basis is mechanistic only; no data either way. #### Injection-Site Reactions and Infection Vials are self-reconstituted and self-administered by subcutaneous (under-the-skin) injection without sterility assurance. Redness, lumps, abscess (pus pocket), or allergic reaction are plausible. Basis is isolated reports with other peptides; none for Testagen. #### Delayed Diagnosis of Treatable Causes Low testosterone or infertility can stem from pituitary tumors, medications, or other diseases. Self-treating with Testagen may postpone that work-up. Basis is clinical reasoning only; no reports exist. ## Risk-Modifying Factors - **Genetic polymorphisms:** no gene variant affecting Testagen breakdown or response is known. Peptidase variants that might slow clearance are unstudied. - **Baseline biomarkers:** an elevated PSA (prostate-specific antigen, a prostate growth marker) or abnormal TSH at baseline raises the stakes of any hormonal or growth effect. - **Sex:** women have no studied use; effects on pregnancy, breastfeeding, and the fetus are entirely unknown. - **Pre-existing conditions:** prostate or other hormone-sensitive cancer, thyroid disease, autoimmune disease, organ transplantation, and weakened immunity heighten theoretical risk. Kidney disease may slow clearance of amino-acid fragments. - **Age:** men over 50, and especially over 65, carry higher baseline prostate-cancer and thyroid-disease rates, so unexpected tissue or hormone effects matter more. ## Key Interactions & Contraindications No interaction has been documented in any study; all entries below are theoretical, based on overlapping targets. - **Testosterone-raising drugs (testosterone, hCG [human chorionic gonadotropin, an LH-mimicking hormone], clomiphene [an estrogen blocker that raises LH]):** caution. Overlapping target obscures which agent drives lab changes. Mitigation: starting one agent at a time and rechecking testosterone after 4–6 weeks separates their effects. - **Thyroid medications (levothyroxine, liothyronine, methimazole):** monitor. Bird data show thyroid-axis shifts; over- or under-replacement could follow. Mitigation: TSH and free T4 are typically rechecked 4–6 weeks after starting. - **Immunosuppressants (drugs that dampen the immune system: tacrolimus, cyclosporine, mycophenolate):** caution. Claimed immune stimulation could oppose transplant or autoimmune therapy, risking rejection or flare. Mitigation: review by the prescribing specialist before any use. - **Anticoagulants (blood thinners: warfarin, apixaban, rivaroxaban):** monitor. Clotting indices shifted in bird studies, so the anticoagulant effect could change, raising bleeding or clotting risk. Mitigation: an INR (clotting time ratio) check within 2 weeks is typical for warfarin users. - **Over-the-counter medications (aspirin, ibuprofen, naproxen):** monitor. No direct interaction known; additive clotting effects are theoretical given bird clotting data. Mitigation: unusual bruising or bleeding signals a possible additive effect. - **Testosterone-supporting supplements (DHEA [dehydroepiandrosterone, a hormone precursor], *Eurycoma longifolia* [tongkat ali], zinc, fenugreek):** caution. Additive hormonal effects and confounded lab interpretation. Mitigation: keeping these unchanged for 4 weeks before and during a course limits confounding. - **Other peptide bioregulators (Testoluten, Epitalon, Thymalin, Prostamax):** caution. Stacking is common and multiplies unknowns and contamination exposure. Mitigation: introducing one new peptide at a time keeps effects attributable. - **Anti-doping testing:** absolute contraindication for tested athletes. WADA (World Anti-Doping Agency) category S0 bans unapproved substances, risking sanctions. **Populations who should avoid Testagen:** - Men with active or treated prostate cancer, or PSA above 4.0 ng/mL (or rising more than 0.75 ng/mL per year) until evaluated - People with any active cancer or cancer treatment within the past 5 years - Pregnant or breastfeeding women - People under 18 years of age - Organ-transplant recipients on immunosuppressants - People with uncontrolled thyroid disease (TSH outside 0.4–4.5 mIU/L) - People with severe kidney impairment (eGFR [estimated glomerular filtration rate, a kidney-function measure] below 30 mL/min/1.73 mΒ²) - Competitive athletes subject to anti-doping testing ## Risk Mitigation Strategies - **Baseline and follow-up hormone panel:** total testosterone, LH, FSH (follicle-stimulating hormone, the pituitary signal for sperm production), TSH, and free T4 measured before starting and 4–6 weeks later detect unexpected thyroid or gonadal shifts. - **Verified sourcing:** lots with independent HPLC (high-performance liquid chromatography, a purity test) purity of at least 98%, mass-spectrometry identity of about 447 daltons, and endotoxin testing reduce contamination and mislabeling risk. - **Aseptic technique:** reconstitution with bacteriostatic (preserved sterile) water, alcohol swabbing of vial and skin, rotating injection sites, and discarding reconstituted solution after 28 days lower the risk of infection and injection-site reactions. - **Prostate screening:** PSA checks at baseline and after each course in men over 45 (over 40 with family history), with a stop threshold of a rise above 0.75 ng/mL, address hormone-sensitive tissue risk. - **Short, defined courses:** courses limited to 10–30 days with at least 3 months off cap cumulative exposure to a compound without long-term safety data. ## Therapeutic Protocol No dose-finding study exists. Two approaches circulate, and conventional options for low testosterone are listed alongside for context. - **Oral developer course:** 2 capsules once or twice daily before meals for 1 month, repeated after 3–6 months, per the developer-linked manufacturer, which profits from sales ([Peptide Bio product page](https://peptide-shop.com/en/peptide-online-store/cytogens-sintesized-peptides/testagen-synthesized-testicular-peptide-detail)). - **Clinically tested regimen:** the one human trial gave 2 capsules twice daily with meals for 30 days alongside prostatitis treatment; its authors report 0.1 mg of peptide per capsule ([Rossikhin et al., 2011](https://jpep.endocrinology.org.ua/index.php/1/article/view/747)). - **Injectable vial course:** online peptide communities report 1–2 mg subcutaneously (under the skin) daily for 10–20 days, 1–3 courses yearly. This stems from vendor convention, not from any study or named clinic. - **Conventional alternatives:** testosterone replacement, clomiphene, or hCG, used by endocrinologists and urologists, have controlled human trial data on testosterone levels; Testagen has one small study without a placebo group. The choice depends on fertility goals and tolerance of monitoring. - **Time of day:** the developer specifies only "before meal", not a time of day; injection users typically dose in the morning. No study compares timing. - **Half-life:** unmeasured. Comparable tetrapeptides are cleared from blood within minutes, so any effect would depend on downstream gene activity rather than sustained blood levels. - **Single vs. split dose:** the oral course allows once or twice daily dosing; injection protocols use one daily dose. No data favor either. - **Genetic polymorphisms:** no pharmacogenetic variant is known to alter Testagen dosing. - **Sex:** protocols exist only for men; no female dose has been proposed or studied. - **Age:** marketed mainly to men over 40. Weaker responses in old hens suggest, without proof, smaller effects with age; no age-adjusted dosing exists. - **Baseline biomarkers:** men with total testosterone below 300 ng/dL and symptoms meet conventional hypogonadism (clinically low testosterone) criteria; Testagen's effect in that group was reported only alongside prostatitis treatment. - **Pre-existing conditions:** no dose adjustment data exist for kidney or liver impairment; lactose in the oral capsules matters for lactose-intolerant users. ## Discontinuation & Cycling - **Short-term by design:** Testagen is used in discrete courses of 10–30 days, not continuously; lasting "epigenetic" benefit after stopping is claimed but untested. - **Withdrawal effects:** none reported. Because Testagen is not a hormone, suppression of the body's own testosterone on stopping is not expected, unlike testosterone replacement. - **Tapering:** not applicable; courses end abruptly in all described protocols. - **Cycling:** cycling is built into every protocol (typically 1–3 courses per year with 3–6 months off). Whether cycling preserves efficacy is unknown, since efficacy itself is unestablished. ## Sourcing and Quality - **Developer-linked oral capsules:** produced by TD Peptide Bio with the St. Petersburg Institute of Bioregulation and Gerontology, which profits from sales. Each 275 mg capsule contains KEDG plus lactose, sugar, starch, cellulose, and polysorbate 80. - **Research-grade injectable vials:** sold as lyophilized (freeze-dried) powder, typically 10–20 mg per vial, labeled "not for human use". They carry no pharmaceutical manufacturing oversight or sterility guarantee. - **What to look for:** a lot-specific certificate of analysis showing HPLC purity of at least 98%, mass-spectrometry mass near 447 daltons, and endotoxin and sterility results, ideally confirmed by an independent laboratory rather than the vendor. - **Compounding pharmacies:** United States compounding pharmacies generally do not supply Testagen, so no pharmacy-grade version is available there. ## Practical Considerations - **Time to effect:** unknown. Vendors claim changes in energy or libido within 2–4 weeks; the one human study reported testosterone changes after one month but measured no time course. - **Name confusion:** "Testagen" is also the brand of an unrelated transdermal testosterone spray tested in [NCT02733133](https://clinicaltrials.gov/study/NCT02733133); searches and purchases can mix the two. - **Common pitfalls:** judging effect by mood or libido without before-and-after labs, stacking several peptides at once, and trusting vendor purity claims without independent testing. - **Regulatory status:** not approved as a drug by the FDA (US Food and Drug Administration) or EMA (European Medicines Agency); sold as a Russian dietary supplement or as a "research chemical". - **Cost and access:** oral packs cost about €69 for 60 capsules; injectable vials cost about $40–$90. No insurer or national health system covers Testagen, so no payer-driven bias for or against it arises. ## Interaction with Foundational Habits - **Sleep:** no direct interaction known. Sleep restriction lowers testosterone by itself, so changes in sleep duration can mask or mimic any Testagen effect; morning dosing avoids attributing evening alertness changes to the peptide. - **Nutrition:** no direct interaction known. Adequate protein, zinc, and vitamin D support testosterone independently; lactose in oral capsules may cause bloating in lactose-intolerant users. Taking capsules before meals follows the developer's instructions, not evidence. - **Exercise:** no direct interaction known; no study examines training response. Resistance training and weight loss raise testosterone independently and are the stronger, evidence-backed levers, so they confound any perceived benefit. - **Stress management:** no direct interaction known. Chronic stress raises cortisol and suppresses testosterone, so shifts in stress load during a course can be misattributed to Testagen. ## Monitoring Protocol & Defining Success Baseline testing before a first course establishes reference values against which any change can be judged, and screens out people for whom Testagen is unsuitable. It includes reproductive hormones, thyroid function, prostate screening, and a general blood and chemistry panel, drawn in the morning while fasting. A semen analysis is added when fertility is the goal. Ongoing monitoring repeats the hormone and thyroid panel 4–6 weeks after starting, again at the end of each course, and then every 6–12 months while courses continue. PSA is rechecked after each course in men over 45, and blood count and chemistry annually. Because no validated response to Testagen exists, success is defined as a sustained, measurable rise over the person's own baseline, confirmed on two morning samples, without adverse changes in thyroid values, PSA, or blood counts. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Total testosterone | 600–900 ng/dL | Main claimed target | Conventional range about 264–916 ng/dL; draw 7–10 a.m., fasting; confirm low values twice | | Free testosterone | About 135–225 pg/mL (upper half of range) | Active hormone fraction | Best by equilibrium dialysis or calculated from total testosterone and SHBG (sex hormone-binding globulin, the carrier protein) | | LH | 2–8 IU/L | Shows whether pituitary drive changes | Conventional range about 1.7–8.6 IU/L; pair with total testosterone | | FSH | 1.5–8 IU/L | Marker of sperm-production drive | Conventional range about 1.5–12.4 IU/L; high values suggest testicular failure | | SHBG | 20–50 nmol/L | Affects free testosterone | Conventional range about 10–57 nmol/L; rises with age and falls with obesity | | Estradiol | 20–30 pg/mL | Estrogen balance in men | Conventional range about 8–35 pg/mL; use a sensitive (LC/MS, liquid chromatography–mass spectrometry) assay | | TSH | 0.5–2.5 mIU/L | Detects thyroid-axis shifts seen in birds | Conventional range about 0.4–4.5 mIU/L; morning draw, pair with free T4 | | Free T4 | 1.0–1.5 ng/dL | Confirms thyroid output | Conventional range about 0.8–1.8 ng/dL; avoid biotin for 48 hours before testing | | PSA | Below 1.0 ng/mL, stable over time | Prostate safety | Conventional cutoff 4.0 ng/mL; avoid ejaculation and cycling for 48 hours before testing | | Semen analysis | Concentration β‰₯ 16 million/mL, progressive motility β‰₯ 30% | Direct fertility outcome | WHO (World Health Organization) 2021 lower reference limits; 2–7 days abstinence; repeat after about 74 days, one sperm cycle | | CBC | Hemoglobin 14–16 g/dL; normal white cells and platelets | General safety | Complete blood count; conventional hemoglobin range about 13.2–17.1 g/dL | | CMP | ALT below 25 U/L; eGFR above 90 mL/min/1.73 mΒ² | Liver and kidney safety | Comprehensive metabolic panel; ALT (alanine aminotransferase, a liver enzyme) conventional upper limit about 45 U/L; fasting | Qualitative markers to track: - Morning erections and libido - Energy and exercise recovery - Mood, motivation, and irritability - Sleep quality - Injection-site redness, swelling, or pain - Palpitations, heat intolerance, or weight change (possible thyroid shifts) ## Emerging Research - **No registered trials:** ClinicalTrials.gov lists no study of KEDG or Testagen as a peptide (no NCT ID exists). The only human data, a small trial without a placebo group or reported randomization ([Rossikhin et al., 2011](https://jpep.endocrinology.org.ua/index.php/1/article/view/747)), have not been repeated; new trials would need independent confirmation. - **Reproductive endpoints:** the central gap. A controlled animal or human study measuring testosterone, LH, or sperm after Testagen could strengthen the case or remove its main rationale. - **Cell delivery:** [Khavinson et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36979488/) predicted by computer modeling that KEDG binds LAT1, LAT2, and PEPT1 strongly. Laboratory uptake and blood-stability tests could confirm or refute that intact Testagen reaches cells. - **Independent laboratories:** [DobriΕ£escu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807317/) studied KEDG as a copper corrosion inhibitor, the first research on the molecule outside the developer network, though with no health endpoint. - **Class-level human data:** [Khavinson & Morozov, 2003](https://pubmed.ncbi.nlm.nih.gov/14523363/) reported lower mortality in 266 elderly people given thymus and pineal peptides; the authors developed these peptides, which their institute sells. Independent replication could support the family; failure would weaken it. Testagen was not tested. - **Sister-peptide research outside Russia:** [Gatta et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40493162/), an Italian university team collaborating with the developer, studied the related tetrapeptide Epitalon in retinal cell models; fully independent replication across the family has not yet appeared. ## Conclusion Testagen is a lab-made four-amino-acid peptide promoted to support male hormone output, fertility, and healthy aging. For health-focused men willing to track their own markers, the central fact is that evidence in people comes from one small study without a placebo or reported random assignment, in men treated at the same time for prostate inflammation. There, men adding Testagen showed higher testosterone and fewer prostate symptoms than men on standard treatment alone, though only changes from starting values were tested. No study has measured effects on sperm or aging. Laboratory work shows it can enter human cells and bind genetic material, and it restored thyroid and immune features in birds whose master hormone gland had been removed. The risk picture is equally thin. No side effects have been recorded, but no one has systematically looked. The most concrete concern is product quality, since most supply comes from unregulated vendors, while effects on thyroid, prostate, and immune function remain possibilities without data. The evidence also has a narrow and interested source. Nearly all biological work comes from the developer's institute and its partners, and that institute earns revenue from selling Testagen and related peptides, a conflict that has not been balanced by independent studies. Vendor claims go well beyond anything the published record shows. Taken together, Testagen stands as a thinly studied member of a larger family of organ-targeted peptides: a single early signal of higher testosterone in men with prostate inflammation, and no evidence yet on fertility or longevity. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**